World News

Under the milestone-based agreement, Sandoz could pay Henlius up to US$322 million, including near-term payments of up to US$100.5 million linked to the initial assets.

Lyme disease is transmitted primarily through the bites of infected ticks.

OmniAb was spun out of Ligand Pharmaceuticals in 2022 and has since built a broad network of pharmaceutical partnerships.

The 95-95-95 targets aim for 95% of people living with HIV to know their status, 95% of those diagnosed to receive antiretroviral treatment, and 95% of those receiving treatment to achieve viral suppression.

The collaboration will focus on designing next-generation photosensitisers for photodynamic therapy (PDT), a treatment that uses light-activated drugs to target and destroy tumour cells.

The device uses controlled freezing to adhere to and remove targeted tissue or foreign material, enabling clinicians to perform both diagnostic and therapeutic interventions through a bronchoscope.

If approved and launched, the vaccine will complement CanSinoBIO’s recently approved three-component DTaP vaccine, Tripecia® (DT3cP Infant), expanding the company’s pertussis-containing vaccine portfolio across age groups.

The company has registered the software as a Software as a Medical Device (SaMD) and says it provides clinical-grade hearing assessment results.

The agreement gives Zealand $50 million upfront, with another $50 million payable one year later.

The sale transfers a business that develops and supplies microbiology products used across clinical diagnostics, pharmaceutical manufacturing and food safety testing.